Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope.
Hybrids of tobacco mosaic virus (TMV) were constructed with the use of fusion to the coat protein peptides of 10 or 15 amino acids, containing the 5B19 epitope from the spike protein of murine hepatitis virus (MHV) and giving rise to TMV-5B19 and TMV-5B19L, respectively. The TMV hybrids were propagated in tobacco plants, and the virus particles were purified. Immunogold labeling, with the use of the monoclonal MAb5B19 antibody, showed specific decoration of hybrid TMV particles, confirming the expression and display of the MHV epitope on the surface of the TMV. Mice were immunized with purified hybrid viruses after several regimens of immunization. Mice that received TMV-5B19L intranasally developed serum IgG and IgA specific for the 5B19 epitope and for the TMV coat protein. Hybrid TMV-5B19, administered by subcutaneous injections, elicited high titers of serum IgG that was specific for the 5B19 epitope and for coat protein, but IgA that was specific against 5B19 was not observed. Mice that were immunized with hybrid virus by subcutaneous or intranasal routes of administration survived challenge with a lethal dose (10 x LD50) of MHV strain JHM, whereas mice administered wild-type TMV died 10 d post challenge. Furthermore, there was a positive correlation between the dose of administered immunogen and protection against MHV infection. These studies show that TMV can be an effective vaccine delivery vehicle for parenteral and mucosal immunization and for protection from challenge with viral infection.
Department of Cell Biology, Division of Plant Biology, BCC 206, La Jolla, CA 92037, USA.
M
M
Koo
M
M
Bendahmane
G A
GA
Lettieri
A D
AD
Paoletti
T E
TE
Lane
J H
JH
Fitchen
M J
MJ
Buchmeier
R N
RN
Beachy
D000281:Administration, Intranasal; D000595:Amino Acid Sequence; D000818:Animals; D000939:Epitopes / Q000008:administration & dosage / Q000276:immunology*; D005260:Female; D006389:Hemagglutinins, Viral / Q000008:administration & dosage / Q000276:immunology; D017325:Hepatitis B Vaccines; D006524:Hepatitis, Viral, Animal / Q000276:immunology* / Q000517:prevention & control; D007115:Immunization Schedule; D007279:Injections, Subcutaneous; D008562:Membrane Glycoproteins / Q000008:administration & dosage / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D006517:Murine hepatitis virus / Q000276:immunology*; D064370:Spike Glycoprotein, Coronavirus; D014027:Tobacco Mosaic Virus / Q000276:immunology*; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins / Q000008:administration & dosage / Q000276:immunology*; D014761:Viral Hepatitis Vaccines
D000939:Epitopes; D006389:Hemagglutinins, Viral; D017325:Hepatitis B Vaccines; D008562:Membrane Glycoproteins; D064370:Spike Glycoprotein, Coronavirus; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014761:Viral Hepatitis Vaccines